Vivasure $185 million exit an Interview with Andrew Glass, CEO
Fri Feb 06 2026
In this episode of The Crux of MedTech, host Henry Norton sits down with Andrew Glass, CEO of Vivasure Medical, fresh off announcing the company's acquisition by Haemonetics Corporation.
Andrew shares the full journey, from his early days in drug-eluting stents at Guidant (later Abbott), to running a $10M sales territory, to making equity investments at Abbott Ventures, and finally taking the leap to lead an Irish medtech startup through a US pivotal trial and strategic exit.
He discusses what it was really like to join a company with two months of cash, why products are never perfect the first time, and the best advice he ever ignored.
Andrew also reveals the hard-won leadership lesson his mentor gave him: "Don't be a jerk."
Key Topics:
The journey from big pharma to startup CEO
How strategic investors evaluate medtech acquisitions
Running US pivotal trials and navigating FDA/CMS challenges
Managing founder dynamics when you're the incoming CEO
Building toward acquisition with option agreements
Related Insights:
Why sales experience is essential for medtech leaders
The value of keeping talent when boards say cut
How timing and strategic fit drive acquisition outcomes
Lessons from raising Series D in a difficult funding environment
Core Challenges:
Joining a startup only to discover there's two months of cash left and having to raise immediately while fixing product issues the board hadn't disclosed.
Navigating CMS approval delays that pushed trial timelines out by 9-12 months, requiring constant execution while waiting for the acquirer's readiness.
🎧 Tune in now for an unfiltered look at what it really takes to lead a medtech startup to exit.
The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.
To learn more about Cruxx, click here.
A big thank you to our sponsors on this season of the podcast;
TTP plc With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, TTP plc can accelerate your development with the latest technologies. Learn more at TTP.com
More
In this episode of The Crux of MedTech, host Henry Norton sits down with Andrew Glass, CEO of Vivasure Medical, fresh off announcing the company's acquisition by Haemonetics Corporation. Andrew shares the full journey, from his early days in drug-eluting stents at Guidant (later Abbott), to running a $10M sales territory, to making equity investments at Abbott Ventures, and finally taking the leap to lead an Irish medtech startup through a US pivotal trial and strategic exit. He discusses what it was really like to join a company with two months of cash, why products are never perfect the first time, and the best advice he ever ignored. Andrew also reveals the hard-won leadership lesson his mentor gave him: "Don't be a jerk." Key Topics: The journey from big pharma to startup CEO How strategic investors evaluate medtech acquisitions Running US pivotal trials and navigating FDA/CMS challenges Managing founder dynamics when you're the incoming CEO Building toward acquisition with option agreements Related Insights: Why sales experience is essential for medtech leaders The value of keeping talent when boards say cut How timing and strategic fit drive acquisition outcomes Lessons from raising Series D in a difficult funding environment Core Challenges: Joining a startup only to discover there's two months of cash left and having to raise immediately while fixing product issues the board hadn't disclosed. Navigating CMS approval delays that pushed trial timelines out by 9-12 months, requiring constant execution while waiting for the acquirer's readiness. 🎧 Tune in now for an unfiltered look at what it really takes to lead a medtech startup to exit. The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx, click here. A big thank you to our sponsors on this season of the podcast; TTP plc With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, TTP plc can accelerate your development with the latest technologies. Learn more at TTP.com